Compare Stocks: QTRX, SIBN, OABI, and DNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNA Ginkgo Bioworks	$6.99 -9.3%	$8.53	$5.37 ▼ $17.58	$519.19M	1.78	1.12 million shs	1.42 million shs
OABI OmniAb	$4.30 +2.6%	$2.48	$1.30 ▼ $4.59	$606.64M	0.45	1.81 million shs	2.25 million shs
QTRX Quanterix	$3.12 +5.4%	$3.61	$2.15 ▼ $8.77	$139.99M	1.07	855,706 shs	579,073 shs
SIBN SiBone	$19.48 -2.2%	$17.40	$11.48 ▼ $21.89	$882.99M	0.66	493,047 shs	518,038 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNA Ginkgo Bioworks	-9.15%	-3.24%	-11.44%	-16.95%	-39.66%
OABI OmniAb	+2.63%	+25.36%	+105.74%	+62.26%	+134.97%
QTRX Quanterix	+5.41%	+9.09%	-21.41%	+15.99%	-36.46%
SIBN SiBone	-2.16%	+2.80%	+14.32%	+32.70%	+25.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNA Ginkgo Bioworks	$6.99 -9.3%	$8.53	$5.37 ▼ $17.58	$519.19M	1.78	1.12 million shs	1.42 million shs
OABI OmniAb	$4.30 +2.6%	$2.48	$1.30 ▼ $4.59	$606.64M	0.45	1.81 million shs	2.25 million shs
QTRX Quanterix	$3.12 +5.4%	$3.61	$2.15 ▼ $8.77	$139.99M	1.07	855,706 shs	579,073 shs
SIBN SiBone	$19.48 -2.2%	$17.40	$11.48 ▼ $21.89	$882.99M	0.66	493,047 shs	518,038 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNA Ginkgo Bioworks	-9.15%	-3.24%	-11.44%	-16.95%	-39.66%
OABI OmniAb	+2.63%	+25.36%	+105.74%	+62.26%	+134.97%
QTRX Quanterix	+5.41%	+9.09%	-21.41%	+15.99%	-36.46%
SIBN SiBone	-2.16%	+2.80%	+14.32%	+32.70%	+25.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNA Ginkgo Bioworks	1.50	Reduce	$7.00	0.14% Upside
OABI OmniAb	2.33	Hold	$11.00	155.81% Upside
QTRX Quanterix	1.67	Reduce	$3.00	-3.85% Downside
SIBN SiBone	2.71	Moderate Buy	$24.17	24.06% Upside

Current Analyst Ratings Breakdown

Latest QTRX, SIBN, OABI, and DNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	DNA Ginkgo Bioworks	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/17/2026	OABI OmniAb	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/17/2026	QTRX Quanterix	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$4.00 ➝ $3.00
8/11/2026	QTRX Quanterix	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$4.00 ➝ $3.00
8/7/2026	QTRX Quanterix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/7/2026	DNA Ginkgo Bioworks	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $9.00
8/6/2026	OABI OmniAb	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	SIBN SiBone	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/4/2026	SIBN SiBone	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $25.00
8/4/2026	SIBN SiBone	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $20.00
8/4/2026	SIBN SiBone	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$21.00 ➝ $23.00

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNA Ginkgo Bioworks	$170.15M	2.77	N/A	N/A	$6.24 per share	1.12
OABI OmniAb	$18.67M	33.35	N/A	N/A	$1.80 per share	2.39
QTRX Quanterix	$138.90M	1.06	N/A	N/A	$5.02 per share	0.62
SIBN SiBone	$213.60M	4.04	N/A	N/A	$4.11 per share	4.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNA Ginkgo Bioworks	-$312.76M	-$5.01	N/A	N/A	N/A	-259.96%	-60.27%	-26.88%	11/5/2026 (Estimated)
OABI OmniAb	-$64.78M	-$0.36	N/A	N/A	N/A	-115.12%	-16.59%	-14.82%	11/3/2026 (Estimated)
QTRX Quanterix	-$107.15M	-$2.63	N/A	N/A	N/A	-80.25%	-26.09%	-19.03%	11/9/2026 (Estimated)
SIBN SiBone	-$18.90M	-$0.34	N/A	N/A	N/A	-6.85%	-8.23%	-6.07%	11/9/2026 (Estimated)

Latest QTRX, SIBN, OABI, and DNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	QTRX Quanterix	-$0.4103	-$1.04	-$0.6297	-$1.04	$37.48 million	$32.91 million
8/6/2026	Q2 2026	OABI OmniAb	-$0.12	-$0.05	+$0.07	-$0.05	$4.69 million	$13.42 million
8/5/2026	Q2 2026	DNA Ginkgo Bioworks	-$0.8950	-$0.75	+$0.1450	-$0.75	$24.05 million	$20.16 million
8/3/2026	Q2 2026	SIBN SiBone	-$0.1495	-$0.09	+$0.0595	-$0.09	$55.34 million	$56.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
OABI OmniAb	N/A	N/A	N/A	N/A	N/A
QTRX Quanterix	N/A	N/A	N/A	N/A	N/A
SIBN SiBone	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNA Ginkgo Bioworks	N/A	4.57	4.57
OABI OmniAb	N/A	4.80	4.80
QTRX Quanterix	N/A	3.40	2.45
SIBN SiBone	0.20	9.15	7.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNA Ginkgo Bioworks	78.63%
OABI OmniAb	72.08%
QTRX Quanterix	86.48%
SIBN SiBone	98.11%

Insider Ownership

Company	Insider Ownership
DNA Ginkgo Bioworks	12.69%
OABI OmniAb	9.80%
QTRX Quanterix	1.50%
SIBN SiBone	4.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNA Ginkgo Bioworks	640	67.34 million	58.80 million	Optionable
OABI OmniAb	7	144.78 million	130.59 million	Optionable
QTRX Quanterix	460	47.29 million	46.58 million	Optionable
SIBN SiBone	350	44.35 million	42.58 million	Optionable

QTRX, SIBN, OABI, and DNA Headlines

Recent News About These Companies

Michael Pisetsky Sells 3,725 Shares of SiBone (NASDAQ:SIBN) Stock

August 19 at 6:22 AM | insidertrades.com

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 3,725 Shares of Stock

August 18 at 5:21 PM | marketbeat.com

Anshul Maheshwari Sells 4,665 Shares of SiBone (NASDAQ:SIBN) Stock

August 18 at 5:21 PM | marketbeat.com

SiBone $SIBN Shares Bought by Dimensional Fund Advisors LP

August 11, 2026 | marketbeat.com

SiBone (NASDAQ:SIBN) Receives Consensus Rating of "Moderate Buy" from Analysts

August 9, 2026 | marketbeat.com

SiBone $SIBN Shares Purchased by Sei Investments Co.

August 7, 2026 | marketbeat.com

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

August 6, 2026 | zacks.com

Insider Selling: SiBone (NASDAQ:SIBN) Director Sells $369,200.00 in Stock

August 6, 2026 | insidertrades.com

Renaissance Technologies LLC Increases Stake in SiBone $SIBN

August 6, 2026 | marketbeat.com

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn Sells 20,000 Shares

August 5, 2026 | marketbeat.com

SiBone's (SIBN) Buy Rating Reaffirmed at Truist Financial

August 4, 2026 | marketbeat.com

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

August 3, 2026 | zacks.com

SiBone Q2 Earnings Call Highlights

August 3, 2026 | marketbeat.com

SiBone (NASDAQ:SIBN) Posts Earnings Results, Beats Estimates By $0.06 EPS

August 3, 2026 | marketbeat.com

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

August 3, 2026 | globenewswire.com

SiBone (NASDAQ:SIBN) Rating Increased to Strong-Buy at UBS Group

July 29, 2026 | marketbeat.com

SiBone (NASDAQ:SIBN) Shares Gap Up - Still a Buy?

July 28, 2026 | marketbeat.com

SI-BONE Inc.

July 27, 2026 | barrons.com

SiBone (SIBN) Projected to Release Quarterly Earnings on Monday

July 27, 2026 | marketbeat.com

First Light Asset Management LLC Has $67.61 Million Stock Holdings in SiBone $SIBN

July 27, 2026 | marketbeat.com

Granahan Investment Management LLC Boosts Holdings in SiBone $SIBN

July 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX, SIBN, OABI, and DNA Company Descriptions

Ginkgo Bioworks NYSE:DNA

$6.99 -0.72 (-9.34%)

Closing price 08/20/2026 03:58 PM Eastern

Extended Trading

$7.04 +0.04 (+0.64%)

As of 04:51 AM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

OmniAb NASDAQ:OABI

$4.30 +0.11 (+2.63%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$4.39 +0.09 (+2.21%)

As of 04:54 AM Eastern

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Quanterix NASDAQ:QTRX

$3.12 +0.16 (+5.41%)

As of 08/20/2026 04:00 PM Eastern

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

SiBone NASDAQ:SIBN

$19.48 -0.43 (-2.16%)

As of 08/20/2026 04:00 PM Eastern

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QTRX, SIBN, OABI, and DNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QTRX, SIBN, OABI, and DNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QTRX, SIBN, OABI, and DNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX, SIBN, OABI, and DNA Company Descriptions

Ginkgo Bioworks NYSE:DNA

OmniAb NASDAQ:OABI

Quanterix NASDAQ:QTRX

SiBone NASDAQ:SIBN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QTRX, SIBN, OABI, and DNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QTRX, SIBN, OABI, and DNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QTRX, SIBN, OABI, and DNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX, SIBN, OABI, and DNA Company Descriptions

Ginkgo Bioworks NYSE:DNA

OmniAb NASDAQ:OABI

Quanterix NASDAQ:QTRX

SiBone NASDAQ:SIBN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools